The Zhitong Finance App learned that Dongyao Pharmaceutical-B (01875) rose nearly 10%. As of press release, it had risen 9.94% to HK$1.99, with a total market value of HK$1,538 billion.
According to the news, Dongyao Pharmaceutical's interim report shows that the company's total revenue for the first half of the year was RMB 328 million, an increase of 80% over the previous year; excluding the impact of license revenue in the first half of 2022, the revenue growth rate reached 147% year on year. In the first half of the year, Dongyao Pharmaceutical's product sales revenue was about 278 million yuan, an increase of 167% over the previous year, mainly from the core product, bevacizumab injection, Park XintingSales volume continues to rise. Revenue from the CDMO/CMO business increased 105% year over year.
Anxin International previously pointed out that the company focuses on the CDMO business fields of biopharmaceuticals such as monoclonal antibodies and ADCs. It has now formed an antibody production capacity of 20,000 L and has built a “unified localization/end-to-end” commercial production platform integrating monoclonal antibodies and ADCs. In recent years, the global and Chinese ADC drug markets have been booming. Due to the complexity of manufacturing processes, the outsourcing rate of ADC formulation production is high. As a leader in the domestic ADC and CDMO fields, the company is expected to benefit from this industry dividend, so it is recommended to keep an eye on it.